Skip to main content
Xvivo Perfusion logo

Xvivo Perfusion — Investor Relations & Filings

Ticker · XVIVO ISIN · SE0004840718 LEI · 549300G2464FYLS14B41 ST Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2018-04-04 Annual Report
Country SE Sweden
Listing ST XVIVO

About Xvivo Perfusion

https://www.xvivogroup.com/

Xvivo Perfusion is a medical technology company specializing in ex-vivo organ preservation for transplantation. The company develops machine perfusion technologies, solutions, and services designed to extend the life of major organs, including lungs, livers, and kidneys. Its core technology, organ perfusion, is an alternative to static cold storage that continuously supplies an organ with an oxygenated solution while it is outside the body. This process helps support cellular function, prevent tissue damage, and allows clinicians to assess organ viability prior to transplant. The company's objective is to increase organ utilization, extend preservation times, and improve patient outcomes. Key products include the XPS™ for lung perfusion, Liver Assist™, Kidney Assist Transport™, and the PERFADEX® Plus solution for lung preservation.

Recent filings

Filing Released Lang Actions
Annual Report 2017
Annual Report Classification · 100% confidence The document is titled 'ÅRSREDOVISNING 2017' (Annual Report 2017) for XVIVO Perfusion AB. It contains a comprehensive table of contents, a summary of the year, management's review (VD har ordet), historical data, financial statements (Räkningar - Koncernen/Moderbolaget), notes, and an audit report (Revisionsberättelse). This is clearly the full annual report for the fiscal year 2017, not an announcement or a summary. FY 2017
2018-04-04 Swedish
Kallelse till årsstämma i XVIVO Perfusion AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "KALLELSE TILL ÅRSSTÄMMA I XVIVO PERFUSION AB (PUBL)" which translates to "NOTICE OF ANNUAL GENERAL MEETING IN XVIVO PERFUSION AB (PUBL)". It details the date, time, location, registration procedures, and the proposed agenda for the meeting. The agenda includes items typical for an AGM, such as electing the chairman, approving the annual report (item 8), deciding on profit distribution (item 9b), electing the board (item 13), and proposing remuneration guidelines (item 15) and share incentive programs (item 16). This content perfectly matches the definition of AGM Information, which corresponds to the code AGM-R.
2018-03-22 Swedish
Annual General Meeting of XVIVO Perfusion AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled "Notice to attend the Annual General Meeting of XVIVO Perfusion AB (publ)" and details the date, location, registration procedures, and the proposed agenda for the meeting. The agenda items cover the election of the chairman, approval of the agenda, presentation of annual accounts, resolutions on profit allocation, remuneration, election of the Board, and authorization for share issues/acquisitions. This content is characteristic of the preparatory materials sent out before an Annual General Meeting (AGM) to solicit shareholder votes and participation. This aligns perfectly with the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, or potentially Proxy Solicitation & Information Statement (PSI) if it were primarily focused on soliciting votes, but the direct invitation and agenda structure strongly suggest AGM-R as the primary classification for the notice itself.
2018-03-22 English
Information from XVIVO Perfusion´s Nomination Committee
Board/Management Information Classification · 99% confidence The document is a press release from XVIVO Perfusion AB dated March 8, 2018, titled "Information from XVIVO Perfusion's Nomination Committee." The content explicitly discusses the Nomination Committee's proposals regarding the re-election and nomination of board members for the upcoming Annual General Meeting (AGM) scheduled for April 27, 2018. This content directly relates to the governance and composition of the board being presented for shareholder approval at the AGM. While it is an announcement, its specific subject matter—proposals for board composition ahead of the AGM—is most closely aligned with the scope of AGM materials or governance information. Since it details the specific proposals intended for the AGM vote, it fits best under AGM Information (AGM-R), which covers presentations and materials shared during the AGM, or potentially Governance Information (CGR). Given the direct reference to the 'Annual General Meeting' and the nature of the proposals (board nominations), AGM-R is the most precise fit for pre-meeting nomination committee announcements.
2018-03-08 English
Information från XVIVO Perfusions Valberedning
Board/Management Information Classification · 99% confidence The document is a press release dated March 8, 2018, titled "Information från XVIVO Perfusions Valberedning" (Information from XVIVO Perfusion's Nomination Committee). It explicitly details the nomination committee's proposals regarding the board of directors for the upcoming Annual General Meeting (AGM) scheduled for April 27, 2018. This content directly relates to the composition of the board and the proposals to be voted on at the AGM. This aligns perfectly with the definition of Board/Management Information (MANG), as it concerns proposed changes to the board members, and also touches upon AGM preparation materials. Since the core content is the proposal for board composition (directors/management), MANG is the most specific fit, although AGM-R is also relevant. Given the focus on proposing new and re-electing directors, MANG is selected as the primary classification.
2018-03-08 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-end Report) for XVIVO Perfusion AB for the year 2017. It contains comprehensive financial statements, including income statements, EBITDA calculations, and management commentary on business performance for both the fourth quarter and the full fiscal year. It is a substantive financial report rather than a mere announcement or summary, fitting the definition of an Interim/Quarterly Report (IR) as it covers a period shorter than a full fiscal year (Q4) and provides detailed financial data. FY 2017
2018-02-09 Swedish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.